Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus causes a spectrum of clinical manifestations, ranging from asymptomatic to mild, moderate, or severe illness with multi-organ failure and death. As we deal with unraveling the damage control measures to square out the burden of the COVID-19 crisis, the conditions of re-infection, co-infection, and the emergence of new viral variants are incessantly inflicting more damage to the human society. To control the spread of the virus and the disease, so far, the research community has appropriately focused its efforts on developing new interventional strategies. Now we are at the right time to advance our clinical and molecular understanding of the emergence of SARS-CoV-2 genetic variants and to decode the mechanistic regulatory network governing the differential host responses to virus or intervention (mainly vaccine).
Relevant to this context, tracking the evolutionary and epidemiological trajectories of the SARS-CoV-2 virus using genetic approaches and identifying the fundamental mechanisms related to the pathogenesis of COVID-19 or its intervention can aid in finding and integrating a sound solution to better manage and/or completely curb the disease. Thus, the goal of this research topic is to call for and engage the scientists and clinicians to disseminate their latest research findings and discoveries, new opinions and perspectives, and methods/protocols (when relevant) on epidemiology and mechanisms underlying COVID-19 and its intervention strategies. We accept all article types, including Case Reports, Protocols, and Technology Reports.
The scope of this research topic is to further our clinical and mechanistic understanding of the emergence of SARS-CoV-2 genetic variants and improving the COVID-19 vaccine efficacy:
1. Immune Escape and Emergence of new variants
2. SARS-CoV-2 Variants of Concern: Host-Pathogen Interaction
3. Methods for the Detection and Identification of SARS-CoV-2 variants
4. Basic Mechanisms of Vaccine Efficacy
5. Tailoring mRNA Vaccines to Counter New Emerging Variants
6. The Impact of Host-related Factors on Vaccine Efficacy
7. Molecular Signatures of SARS-CoV-2 Immunity and COVID-19 Vaccine Immunogenicity
8. Preclinical or Clinical Studies of Repurposed Pharmacological Agents, Small-Molecule Drugs, and anti-viral agents for the treatment of COVID-19.
Dr. Alagarraju Muthukumar is currently funded by Regeneron, Abbott Diagnostics.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus causes a spectrum of clinical manifestations, ranging from asymptomatic to mild, moderate, or severe illness with multi-organ failure and death. As we deal with unraveling the damage control measures to square out the burden of the COVID-19 crisis, the conditions of re-infection, co-infection, and the emergence of new viral variants are incessantly inflicting more damage to the human society. To control the spread of the virus and the disease, so far, the research community has appropriately focused its efforts on developing new interventional strategies. Now we are at the right time to advance our clinical and molecular understanding of the emergence of SARS-CoV-2 genetic variants and to decode the mechanistic regulatory network governing the differential host responses to virus or intervention (mainly vaccine).
Relevant to this context, tracking the evolutionary and epidemiological trajectories of the SARS-CoV-2 virus using genetic approaches and identifying the fundamental mechanisms related to the pathogenesis of COVID-19 or its intervention can aid in finding and integrating a sound solution to better manage and/or completely curb the disease. Thus, the goal of this research topic is to call for and engage the scientists and clinicians to disseminate their latest research findings and discoveries, new opinions and perspectives, and methods/protocols (when relevant) on epidemiology and mechanisms underlying COVID-19 and its intervention strategies. We accept all article types, including Case Reports, Protocols, and Technology Reports.
The scope of this research topic is to further our clinical and mechanistic understanding of the emergence of SARS-CoV-2 genetic variants and improving the COVID-19 vaccine efficacy:
1. Immune Escape and Emergence of new variants
2. SARS-CoV-2 Variants of Concern: Host-Pathogen Interaction
3. Methods for the Detection and Identification of SARS-CoV-2 variants
4. Basic Mechanisms of Vaccine Efficacy
5. Tailoring mRNA Vaccines to Counter New Emerging Variants
6. The Impact of Host-related Factors on Vaccine Efficacy
7. Molecular Signatures of SARS-CoV-2 Immunity and COVID-19 Vaccine Immunogenicity
8. Preclinical or Clinical Studies of Repurposed Pharmacological Agents, Small-Molecule Drugs, and anti-viral agents for the treatment of COVID-19.
Dr. Alagarraju Muthukumar is currently funded by Regeneron, Abbott Diagnostics.